Literature DB >> 21924760

Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study.

Robby Nieuwlaat1, Benjamin J Connolly, Lowiek M Hubers, Spencer M Cuddy, John W Eikelboom, Salim Yusuf, Stuart J Connolly.   

Abstract

INTRODUCTION: Time in therapeutic range (TTR) for international normalized ratio (INR) is an accepted quality measure of anticoagulation control in patient populations, but its usefulness for predicting stroke and bleeding in individuals is not well understood.
MATERIALS AND METHODS: In a nested case control analysis among ACTIVE W study patients, cases with stroke and cases with bleeding were separately matched with controls. Several anticoagulation quality measures were compared, overall and in a time-dependent manner.
RESULTS: 32 cases with ischemic stroke and 234 cases with bleeding in the analysis were matched in a 4:1 ratio to 122 and 865 controls, respectively. Follow-up duration was 257±154days for the stroke analysis and 222±146days for the bleeding analysis. Compared with their respective controls, the study mean TTR of both stroke cases (53.9%±25.1 vs 63.4%±24.8; p=0.055) and bleeding cases (56.2%±25.4 vs 63.4%±26.8; p<0.001) was lower. Time below range for stroke and time above range for bleeding were only greater in the last month leading up to the event, not over the entire study period. Rather, over the entire study period bleeding cases spent more time below range than controls (26.8%±25.9 vs 20.8%±24.0; p=0.001).
CONCLUSIONS: TTR was lower in individual AF patients with stroke or bleeding compared with matched controls in ACTIVE W. Maintaining a high TTR, with equal importance to avoid low and high INRs, is a relevant goal of individual patient treatment to prevent stroke and bleeding.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924760     DOI: 10.1016/j.thromres.2011.08.024

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  15 in total

1.  The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study.

Authors:  Alberto Tosetto; Sophie Testa; Gualtiero Palareti; Oriana Paoletti; Ilaria Nichele; Francesca Catalano; Rossella Morandini; Maria Di Paolo; Maurizio Tala; Pilar Esteban; Francesco Cora'; Salvatore Mannino; Anna Maroni; Maria Sessa; Giancarlo Castaman
Journal:  Intern Emerg Med       Date:  2019-07-15       Impact factor: 3.397

2.  Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012.

Authors:  Paul L Hess; Michael J Mirro; Hans-Christoph Diener; John W Eikelboom; Sana M Al-Khatib; Elaine M Hylek; Hayden B Bosworth; Bernard J Gersh; Daniel E Singer; Greg Flaker; Jessica L Mega; Eric D Peterson; John S Rumsfeld; Benjamin A Steinberg; Ajay K Kakkar; Robert M Califf; Christopher B Granger
Journal:  Am Heart J       Date:  2014-04-24       Impact factor: 4.749

3.  Adherence to warfarin treatment among patients with atrial fibrillation.

Authors:  Mika Skeppholm; Leif Friberg
Journal:  Clin Res Cardiol       Date:  2014-07-31       Impact factor: 5.460

4.  Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.

Authors:  Sadık Volkan Emren; Mehdi Zoghi; Rida Berilgen; İbrahim Halil Özdemir; Oğuzhan Çelik; Nurullah Çetin; Asım Enhoş; Cemal Köseoğlu; Abdurrahman Akyüz; Volkan Doğan; Fatih Levent; Yüksel Dereli; Tolga Doğan; Özcan Başaran; Ilgın Karaca; Özkan Karaca; Yılmaz Ömür Otlu; Çağlar Özmen; Selvi Coşar; Mutlu Sümerkan; Erdal Gürsul; Sinan İnci; Ersel Onrat; Oktay Ergene
Journal:  Bosn J Basic Med Sci       Date:  2018-05-20       Impact factor: 3.363

5.  Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management.

Authors:  Salah Abohelaika; Hilary Wynne; Peter Avery; Brian Robinson; Patrick Kesteven; Farhad Kamali
Journal:  Br J Clin Pharmacol       Date:  2016-07-24       Impact factor: 4.335

Review 6.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

7.  Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study.

Authors:  Cynthia Wu; Michael Sean McMurtry; Roopinder K Sandhu; Erik Youngson; Justin A Ezekowitz; Padma Kaul; Finlay A McAlister
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

Review 8.  Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences.

Authors:  Jeff R Schein; C Michael White; Winnie W Nelson; Jeffrey Kluger; Elizabeth S Mearns; Craig I Coleman
Journal:  Thromb J       Date:  2016-06-13

9.  Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial.

Authors:  Leiliane Rodrigues Marcatto; Luciana Sacilotto; Carolina Tosin Bueno; Mirella Facin; Celia Maria Cassaro Strunz; Francisco Carlos Costa Darrieux; Maurício Ibrahim Scanavacca; Jose Eduardo Krieger; Alexandre Costa Pereira; Paulo Caleb Junior Lima Santos
Journal:  BMC Cardiovasc Disord       Date:  2016-11-17       Impact factor: 2.298

10.  Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation.

Authors:  Alberto Tosetto; Cesare Manotti; Francesco Marongiu
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.